Denali Therapeutics has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $195 million. The voucher was granted following the FDA accelerated approval of Avlayah in March 2026 for Hunter syndrome. The transaction provides a significant non-dilutive capital infusion to strengthen the company's balance sheet and advance its TransportVehicle-enabled clinical portfolio. The sale remains subject to customary closing conditions including antitrust clearance. Denali shares have gained 41.2% year to date against an industry decline of 1.7%.
Denali Therapeutics IncDenali sells PRV for $195M, providing non-dilutive capital to strengthen balance sheet and advance pipeline.
Takeda Pharmaceutical Co. Ltd.
Biogen Inc
Sanofi SA